 |
Journal articles
mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease
Jingsong Cao
1
Minjung Choi
1
Eleonora Guadagnin
1
Maud Soty
2
Marine Silva
2
Vincent Verzieux
2
Edward Weisser
1
Arianna Markel
1
Jenny Zhuo
1
Shi Liang
1
Ling Yin
1
Andrea Frassetto
1
Anne-Renee Graham
3
Kristine Burke
3
Tatiana Ketova
3
Cosmin Mihai
3
Zach Zalinger
3
Becca Levy
3
Gilles Besin
3
Meredith Wolfrom
3
Barbara Tran
3
Christopher Tunkey
3
Erik Owen
3
Joe Sarkis
3
Athanasios Dousis
3
Vladimir Presnyak
3
Christopher Pepin
3
Wei Zheng
3
Lei Ci
3
Marjie Hard
3
Edward Miracco
3
Lisa Rice
1
Vi Nguyen
1
Mike Zimmer
1
Uma Rajarajacholan
1
Patrick Finn
1
Gilles Mithieux
2
Fabienne Rajas
2
Paolo Martini
1
Paloma Giangrande
1, *
*
Corresponding author
Gilles Mithieux 2
Author
Fabienne Rajas 2
Author
Paolo Martini 1
Author
Paloma Giangrande 1
Correspondent author
1
Moderna Inc - Rare Diseases [Cambridge, MA, USA] (United States)
- Moderna Inc [Cambridge, MA, USA] (United States)
2
Nutrition, diabète et cerveau (FACULTE DE MEDECINE LYON EST LAENNEC
7 RUE GUILLAUME PARADIN
BAT B 1ER ETAGE
69372 LYON
CEDEX 08
- France)
- UCBL - Université Claude Bernard Lyon 1 (43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex - France)
- Université de Lyon (92 rue Pasteur - CS 30122, 69361 Lyon Cedex 07 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1213 (101, rue de Tolbiac, 75013 Paris - France)
3
Moderna Inc - Platform [Cambridge, MA, USA] (United States)
- Moderna Inc [Cambridge, MA, USA] (United States)
Abstract : Abstract Glycogen Storage Disease 1a (GSD1a) is a rare, inherited metabolic disorder caused by deficiency of glucose 6-phosphatase (G6Pase-α). G6Pase-α is critical for maintaining interprandial euglycemia. GSD1a patients exhibit life-threatening hypoglycemia and long-term liver complications including hepatocellular adenomas (HCAs) and carcinomas (HCCs). There is no treatment for GSD1a and the current standard-of-care for managing hypoglycemia (Glycosade ® /modified cornstarch) fails to prevent HCA/HCC risk. Therapeutic modalities such as enzyme replacement therapy and gene therapy are not ideal options for patients due to challenges in drug-delivery, efficacy, and safety. To develop a new treatment for GSD1a capable of addressing both the life-threatening hypoglycemia and HCA/HCC risk, we encapsulated engineered mRNAs encoding human G6Pase-α in lipid nanoparticles. We demonstrate the efficacy and safety of our approach in a preclinical murine model that phenotypically resembles the human condition, thus presenting a potential therapy that could have a significant therapeutic impact on the treatment of GSD1a.
Document type :
Journal articles
Complete list of metadata
https://www.hal.inserm.fr/inserm-03257867
Contributor : Marie-Ange Di Carlo Connect in order to contact the contributor
Submitted on : Friday, June 11, 2021 - 10:45:56 AM
Last modification on : Saturday, June 12, 2021 - 3:23:18 AM
Contributor : Marie-Ange Di Carlo Connect in order to contact the contributor
Submitted on : Friday, June 11, 2021 - 10:45:56 AM
Last modification on : Saturday, June 12, 2021 - 3:23:18 AM
File
s41467-021-23318-2.pdf
Publication funded by an institution
Identifiers
- HAL Id : inserm-03257867, version 1
- DOI : 10.1038/s41467-021-23318-2
- PUBMED : 34035281
- PUBMEDCENTRAL : PMC8149455
Collections
INSERM | UNIV-LYON1 | UDL
Citation
Jingsong Cao, Minjung Choi, Eleonora Guadagnin, Maud Soty, Marine Silva, et al.. mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.3090. ⟨10.1038/s41467-021-23318-2⟩. ⟨inserm-03257867⟩
Metrics
Les métriques sont temporairement indisponibles